Synthetic DNA is used in many cutting edge technologies from industrial biotech, to medicine, agriculture and beyond. However, synthetic DNA's potential has not been fully realized due to the inefficient, 30+ year old method of chemically synthesizing DNA. The current process is limited in output to relatively short DNA sequences and its purity is often less than ideal. In contrast, iSelect portfolio company, Molecular Assemblies, is pioneering a state of the art enzymatic DNA synthesis technology that can scale to produce longer synthetic DNA, which can unlock advances in many different fields.Hear about Molecular Assemblies and the end markets that its enzymatic DNA synthesis technology unlocks. We will be joined by Molecular Assemblies CEO Mike Kamdar, Codexis President & CEO John Nicols, and guests who are potential customers of synthetic DNA.

Ver todos los episodios